Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
MarketBeat on MSN12h
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Healthline3mon
Mounjaro (tirzepatide) Price, Savings, and Coupon
If you don’t have insurance, you can visit Optum Perks to get price estimates for Mounjaro when you use coupons from the site. (Optum Perks is a sister site of Healthline.) Optum Perks coupons ...
Business Insider on MSN6d
See ya, knock-off Ozempic
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Healthcare Dive11d
Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.
Novo sells semaglutide as Ozempic, Rybelsus and Wegovy. The CMS will treat the different forms as a single product in price ...
Lexaria Bioscience price target lowered to $7 from $10 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Lexaria Bioscience (LEXX) to $7 from $10 and keeps a Buy rating on the ...
Yahoo1mon
The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result.
at a significantly lower cost — around $250 to $350 per month for tirzepatide, compared to Zepbound's list price of $1,059. With the official shortage over, the FDA has signaled it will crack ...